Citation Impact
Citing Papers
Assembly of a Functional HCV Glycoprotein Heterodimer
2007
Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro
2006 StandoutNobel
Neutralizing antibody response during acute and chronic hepatitis C virus infection
2004 StandoutNobel
Complete Replication of Hepatitis C Virus in Cell Culture
2005 StandoutScienceNobel
Characterization of a canine homolog of hepatitis C virus
2011 StandoutNobel
Superinfection Exclusion in Cells Infected with Hepatitis C Virus
2007 StandoutNobel
Hepatitis C Virus E2 Envelope Glycoprotein Core Structure
2013 Science
Mouse models of acute and chronic hepacivirus infection
2017 StandoutScienceNobel
Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1)
2013 StandoutNobel
Three conformational snapshots of the hepatitis C virus NS3 helicase reveal a ratchet translocation mechanism
2009 StandoutNobel
Characterization of Hepatitis C Virus Particle Subpopulations Reveals Multiple Usage of the Scavenger Receptor BI for Entry Steps
2012
Early steps of the hepatitis C virus life cycle
2008
Cell Culture Systems for Hepatitis C Virus
2013
Hepatitis C virus entry into host cells
2007
SEC14L2 enables pan-genotype HCV replication in cell culture
2015 StandoutNatureNobel
Evaluation of ITX 5061, a Scavenger Receptor B1 Antagonist: Resistance Selection and Activity in Combination With Other Hepatitis C Virus Antivirals
2012
Completion of the entire hepatitis C virus life cycle in genetically humanized mice
2013 StandoutNatureNobel
Hepatitis C virus E1 envelope glycoprotein interacts with apolipoproteins in facilitating entry into hepatocytes
2011
Serum amyloid A has antiviral activity against hepatitis C virus by inhibiting virus entry in a cell culture system
2006
Role of lipid metabolism in hepatitis C virus assembly and entry
2009
Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo
2008
Unravelling hepatitis C virus replication from genome to function
2005 StandoutNatureNobel
Applying antibody-sensitive hypervariable region 1-deleted hepatitis C virus to the study of escape pathways of neutralizing human monoclonal antibody AR5A
2017
The Disulfide Bonds in Glycoprotein E2 of Hepatitis C Virus Reveal the Tertiary Organization of the Molecule
2010
Early infection events highlight the limited transmissibility of hepatitis C virus in vitro
2013
Cell Entry of Hepatitis C Virus Requires a Set of Co-receptors That Include the CD81 Tetraspanin and the SR-B1 Scavenger Receptor
2003
Complete Predicted Three-Dimensional Structure of the Facilitator Transmembrane Protein and Hepatitis C Virus Receptor CD81: Conserved and Variable Structural Domains in the Tetraspanin Superfamily
2005
Receptors and routes of dengue virus entry into the host cells
2015
Crystal Structure of HIV-1 gp41 Including Both Fusion Peptide and Membrane Proximal External Regions
2010
Hepatitis C Virus Is Primed by CD81 Protein for Low pH-dependent Fusion
2011
Progress in the development of preventive and therapeutic vaccines for hepatitis C virus
2011
microRNA-122 stimulates translation of hepatitis C virus RNA
2008
HCV E2 core structures and mAbs: something is still missing
2014
Hepatitis C Virus Continuously Escapes From Neutralizing Antibody and T-Cell Responses During Chronic Infection In Vivo
2006 StandoutNobel
Hepatitis C virus epitope exposure and neutralization by antibodies is affected by time and temperature
2011
Cell entry of hepatitis C virus
2006
The past, present and future of neutralizing antibodies for hepatitis C virus
2014
Safety and Antiviral Activity of the HCV Entry Inhibitor ITX5061 in Treatment-Naive HCV-Infected Adults: A Randomized, Double-Blind, Phase 1b Study
2013
Non-random Escape Pathways from a Broadly Neutralizing Human Monoclonal Antibody Map to a Highly Conserved Region on the Hepatitis C Virus E2 Glycoprotein Encompassing Amino Acids 412–423
2014
HCV glycoprotein structures: what to expect from the unexpected
2015
Hepatitis C Virus Proteins: From Structure to Function
2013
Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors
2010
RNA Interference and Single Particle Tracking Analysis of Hepatitis C Virus Endocytosis
2009
Prospects for a vaccine against the hepatitis C virus
2005 StandoutNatureNobel
Structure of the core ectodomain of the hepatitis C virus envelope glycoprotein 2
2014 Nature
Sensitive luminescent reporter viruses reveal appreciable release of hepatitis C virus NS5A protein into the extracellular environment
2017
A Human Monoclonal Antibody Targeting Scavenger Receptor Class B Type I Precludes Hepatitis C Virus Infection and Viral Spread In Vitro and In Vivo
2011 StandoutNobel
High Density Lipoprotein Inhibits Hepatitis C Virus-neutralizing Antibodies by Stimulating Cell Entry via Activation of the Scavenger Receptor BI
2006
Adaptive Immunity to the Hepatitis C Virus
2010
C-type Lectins L-SIGN and DC-SIGN Capture and Transmit Infectious Hepatitis C Virus Pseudotype Particles
2004
Structural characterization of the transmembrane proximal region of the hepatitis C virus E1 glycoprotein
2009
Structural Details of HIV-1 Recognition by the Broadly Neutralizing Monoclonal Antibody 2F5: Epitope Conformation, Antigen-Recognition Loop Mobility, and Anion-Binding Site
2008
The Humoral Immune Response to HCV: Understanding is Key to Vaccine Development
2014
CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells
2008 StandoutNobel
The ins and outs of hepatitis C virus entry and assembly
2013 StandoutNobel
Human occludin is a hepatitis C virus entry factor required for infection of mouse cells
2009 StandoutNatureNobel
Temporal Analysis of Hepatitis C Virus Cell Entry with Occludin Directed Blocking Antibodies
2013
Critical interaction between E1 and E2 glycoproteins determines binding and fusion properties of hepatitis C virus during cell entry
2013
Adaptation of Hepatitis C Virus to Mouse CD81 Permits Infection of Mouse Cells in the Absence of Human Entry Factors
2010
Structure–function analysis of hepatitis C virus envelope glycoproteins E1 and E2
2014
Kinetics of HCV envelope proteins’ interaction with CD81 large extracellular loop
2005
Characterization of host‐range and cell entry properties of the major genotypes and subtypes of hepatitis C virus†
2005
Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry
2007 StandoutNatureNobel
A diverse range of gene products are effectors of the type I interferon antiviral response
2011 StandoutNatureNobel
Mutagenesis of the fusion peptide-like domain of hepatitis C virus E1 glycoprotein: involvement in cell fusion and virus entry
2009
T cell immunity to hepatitis C virus: Lessons for a prophylactic vaccine
2020
Genome-Scale Identification of SARS-CoV-2 and Pan-coronavirus Host Factor Networks
2020 StandoutNobel
Hepatitis C Virus Entry
2007 StandoutNobel
Virion Assembly and Release
2013
Structure of a Pestivirus Envelope Glycoprotein E2 Clarifies Its Role in Cell Entry
2012
The Exchangeable Apolipoprotein ApoC-I Promotes Membrane Fusion of Hepatitis C Virus
2007
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
2014 Standout
Hepatitis C virus receptors claudin-1 and occludin after liver transplantation and influence on early viral kinetics
2010
Challenges and Promise of a Hepatitis C Virus Vaccine
2019
Hepatitis C virus entry into hepatocytes: Molecular mechanisms and targets for antiviral therapies
2010
A genetically humanized mouse model for hepatitis C virus infection
2011 StandoutNatureNobel
Monoclonal Anti-Claudin 1 Antibodies Prevent Hepatitis C Virus Infection of Primary Human Hepatocytes
2010
Unexpected structure for the N-terminal domain of hepatitis C virus envelope glycoprotein E1
2014
Scavenger receptor class B type I and the hypervariable region-1 of hepatitis C virus in cell entry and neutralisation
2011
Novel Insights into Hepatitis C Virus Replication and Persistence
2004
A single point mutation in E2 enhances hepatitis C virus infectivity and alters lipoprotein association of viral particles
2009
Functional hepatitis C virus envelope glycoproteins
2004
Human Monoclonal Antibodies to a Novel Cluster of Conformational Epitopes on HCV E2 with Resistance to Neutralization Escape in a Genotype 2a Isolate
2012
TMEM41B Is a Pan-flavivirus Host Factor
2020 StandoutNobel
How hepatitis C virus invades hepatocytes: The mystery of viral entry
2014
Development of Virus-Like Particle Technology from Small Highly Symmetric to Large Complex Virus-Like Particle Structures
2013 Standout
Replication of hepatitis C virus
2007 StandoutNobel
A novel membrane fusion protein family in Flaviviridae?
2014
Hepatitis C Virus RNA Functionally Sequesters miR-122
2015 StandoutNobel
Transmembrane Domains of Hepatitis C Virus Envelope Glycoproteins: Residues Involved in E1E2 Heterodimerization and Involvement of These Domains in Virus Entry
2006
Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles
2003 StandoutNobel
Mutations within a Conserved Region of the Hepatitis C Virus E2 Glycoprotein That Influence Virus-Receptor Interactions and Sensitivity to Neutralizing Antibodies
2010
Structure and Function of the Hepatitis C Virus Envelope Glycoproteins E1 and E2: Antiviral and Vaccine Targets
2016 StandoutNobel
Structure of the HIV-1 gp41 Membrane-Proximal Ectodomain Region in a Putative Prefusion Conformation,
2009
CD81-Dependent Binding of Hepatitis C Virus E1E2 Heterodimers
2003
The role of neutralizing antibodies in hepatitis C virus infection
2011
Hepatitis C Virus Envelope Glycoprotein E1 Forms Trimers at the Surface of the Virion
2015
A Library of Infectious Hepatitis C Viruses with Engineered Mutations in the E2 Gene Reveals Growth-Adaptive Mutations That Modulate Interactions with Scavenger Receptor Class B Type I
2016
Blocking Hepatitis C Virus Infection with Recombinant Form of Envelope Protein 2 Ectodomain
2009
Sulfated Homologues of Heparin Inhibit Hepatitis C Virus Entry into Mammalian Cells
2007
Rational HIV Immunogen Design to Target Specific Germline B Cell Receptors
2013 StandoutScienceNobel
Hepatitis C Virus Entry
2013
Recombinant Hepatitis C Virus Envelope Glycoprotein Vaccine Elicits Antibodies Targeting Multiple Epitopes on the Envelope Glycoproteins Associated with Broad Cross-Neutralization
2014 StandoutNobel
Unexpected Structural Features of the Hepatitis C Virus Envelope Protein 2 Ectodomain
2014
Ultrastructural analysis of hepatitis C virus particles
2013 StandoutNobel
Identification of New Functional Regions in Hepatitis C Virus Envelope Glycoprotein E2
2010
Broadly Neutralizing Immune Responses against Hepatitis C Virus Induced by Vectored Measles Viruses and a Recombinant Envelope Protein Booster
2012 StandoutNobel
Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus
2012 StandoutNobel
Hepatitis C virus cell entry: role of lipoproteins and cellular receptors
2009
Modeling hepatitis C virus infection using human induced pluripotent stem cells
2012 StandoutNobel
Diverse Hepatitis C Virus Glycoproteins Mediate Viral Infection in a CD81-Dependent Manner
2004 StandoutNobel
Isolation and Characterization of Broadly Neutralizing Human Monoclonal Antibodies to the E1 Glycoprotein of Hepatitis C Virus
2007
CD81 is an entry coreceptor for hepatitis C virus
2004
A bacterial Argonaute with noncanonical guide RNA specificity
2016 StandoutNobel
High-density lipoproteins reduce the neutralizing effect of hepatitis C virus (HCV)-infected patient antibodies by promoting HCV entry
2006
Initiation of Hepatitis C Virus Infection Is Dependent on Cholesterol and Cooperativity between CD81 and Scavenger Receptor B Type I
2006
A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance
2015
In vitro assay for neutralizing antibody to hepatitis C virus: Evidence for broadly conserved neutralization epitopes
2003
A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1
2019 StandoutNobel
Computational Prediction of the Heterodimeric and Higher-Order Structure of gpE1/gpE2 Envelope Glycoproteins Encoded by Hepatitis C Virus
2017 StandoutNobel
Hepatitis C Virus Entry Depends on Clathrin-Mediated Endocytosis
2006
Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation
2010
Hepatitis C Virus Evasion Mechanisms from Neutralizing Antibodies
2011
Structural and Antigenic Definition of Hepatitis C Virus E2 Glycoprotein Epitopes Targeted by Monoclonal Antibodies
2013
Functional Analysis of Hepatitis C Virus Envelope Proteins, Using a Cell-Cell Fusion Assay
2006
Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein
2008
Studying Hepatitis C Virus: Making the Best of a Bad Virus
2007 StandoutNobel
Hepatitis C virus entry: potential receptors and their biological functions
2006
Neutralizing Antibody-Resistant Hepatitis C Virus Cell-to-Cell Transmission
2010
Characterization of Infectious Retroviral Pseudotype Particles Bearing Hepatitis C Virus Glycoproteins
2004 StandoutNobel
Hepatitis C Virus NS2 Protein Contributes to Virus Particle Assembly via Opposing Epistatic Interactions with the E1-E2 Glycoprotein and NS3-NS4A Enzyme Complexes
2009
Hypervariable region 1 shielding of hepatitis C virus is a main contributor to genotypic differences in neutralization sensitivity
2016
Incorporation of Hepatitis C Virus E1 and E2 Glycoproteins: The Keystones on a Peculiar Virion
2014
Characterization of Functional Hepatitis C Virus Envelope Glycoproteins
2004
Impact of Intra- and Interspecies Variation of Occludin on Its Function as Coreceptor for Authentic Hepatitis C Virus Particles
2011
Blocking HCV Entry as Potential Antiviral Therapy
2012
Cellular cofactors affecting hepatitis C virus infection and replication
2007 StandoutNobel
Pharmacokinetics and Safety in Cynomolgus Monkeys of a Monoclonal Antibody Targeting Human Scavenger Receptor Class B Type-1 for Hepatitis C Treatment
2013
Hypervariable Region 1 Deletion and Required Adaptive Envelope Mutations Confer Decreased Dependency on Scavenger Receptor Class B Type I and Low-Density Lipoprotein Receptor for Hepatitis C Virus
2013
Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs
2002 StandoutNobel
Neutralizing Monoclonal Antibodies against Hepatitis C Virus E2 Protein Bind Discontinuous Epitopes and Inhibit Infection at a Postattachment Step
2011
A Hepatitis C Virus Envelope Polymorphism Confers Resistance to Neutralization by Polyclonal Sera and Broadly Neutralizing Monoclonal Antibodies
2016
Hepatitis C Virus Induces CD81 and Claudin-1 Endocytosis
2012
Human Serum Facilitates Hepatitis C Virus Infection, and Neutralizing Responses Inversely Correlate with Viral Replication Kinetics at the Acute Phase of Hepatitis C Virus Infection
2005
Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agents
2014 StandoutNobel
Activation of naïve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders
2005 StandoutNobel
Virus‐neutralizing antibodies to hepatitis C virus
2013
Hepatitis C Virus Hypervariable Region 1 Modulates Receptor Interactions, Conceals the CD81 Binding Site, and Protects Conserved Neutralizing Epitopes
2010
Design of a hyperstable 60-subunit protein icosahedron
2016 StandoutNatureNobel
Persistent hepatitis C virus infection in microscale primary human hepatocyte cultures
2010 StandoutNobel
Comprehensive linker-scanning mutagenesis of the hepatitis C virus E1 and E2 envelope glycoproteins reveals new structure–function relationships
2011
Diverse CD81 Proteins Support Hepatitis C Virus Infection
2006 StandoutNobel
The Multifaceted Roles of Autophagy in Flavivirus-Host Interactions
2018
Role of N-Linked Glycans in the Functions of Hepatitis C Virus Envelope Glycoproteins
2005
Structural insights into key sites of vulnerability on HIV ‐1 Env and influenza HA
2012
The Membrane-Active Regions of the Hepatitis C Virus E1 and E2 Envelope Glycoproteins
2006
Different Domains of CD81 Mediate Distinct Stages of Hepatitis C Virus Pseudoparticle Entry
2006
Internal Disequilibria and Phenotypic Diversification during Replication of Hepatitis C Virus in a Noncoevolving Cellular Environment
2017 StandoutNobel
Ultrastructural and Biophysical Characterization of Hepatitis C Virus Particles Produced in Cell Culture
2010
Identification of Conserved Residues in the E2 Envelope Glycoprotein of the Hepatitis C Virus That Are Critical for CD81 Binding
2006
Different Requirements for Scavenger Receptor Class B Type I in Hepatitis C Virus Cell-Free versus Cell-to-Cell Transmission
2013 StandoutNobel
Modified E2 Glycoprotein of Hepatitis C Virus Enhances Proinflammatory Cytokines and Protective Immune Response
2022 StandoutNobel
Elicitation of structure-specific antibodies by epitope scaffolds
2010 StandoutNobel
Hypervariable Region 1 Differentially Impacts Viability of Hepatitis C Virus Strains of Genotypes 1 to 6 and Impairs Virus Neutralization
2010
Crystal structure of glycoprotein E2 from bovine viral diarrhea virus
2013
Role of Scavenger Receptor Class B Type I in Hepatitis C Virus Entry: Kinetics and Molecular Determinants
2009 StandoutNobel
Targeting HCV Entry For Development of Therapeutics
2010
Contribution of the charged residues of hepatitis C virus glycoprotein E2 transmembrane domain to the functions of the E1E2 heterodimer
2005
Structure of the catalytic domain of the hepatitis C virus NS2-3 protease
2006 StandoutNatureNobel
Works of Heidi E. Drummer being referenced
Hepatitis C Virus (HCV) Envelope Glycoproteins E1 and E2 Contain Reduced Cysteine Residues Essential for Virus Entry
2011
Expression and biochemical analysis of the entire HIV‐2 gp41 ectodomain: determinants of stability map to N‐ and C‐terminal sequences outside the 6‐helix bundle core
2004
The Potential Impact of a Hepatitis C Vaccine for People Who Inject Drugs: Is a Vaccine Needed in the Age of Direct-Acting Antivirals?
2016
High Rates of Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfection in People Who Inject Drugs: A Prospective Cohort Study
2013
The case for a universal hepatitis C vaccine to achieve hepatitis C elimination
2019
Challenges to the development of vaccines to hepatitis C virus that elicit neutralizing antibodies
2014
Cell surface expression of functional hepatitis C virus E1 and E2 glycoproteins
2003
Immunological responses following administration of a genotype 1a/1b/2/3a quadrivalent HCV VLP vaccine
2018
The SR-BI Partner PDZK1 Facilitates Hepatitis C Virus Entry
2010
Claudin Association with CD81 Defines Hepatitis C Virus Entry
2010
A self‐adjuvanting multiepitope immunogen that induces a broadly cross‐reactive antibody to hepatitis C virus†
2007
The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments
2015
The variable regions of hepatitis C virus glycoprotein E2 have an essential structural role in glycoprotein assembly and virion infectivity
2010
Functional Links between the Fusion Peptide-proximal Polar Segment and Membrane-proximal Region of Human Immunodeficiency Virus gp41 in Distinct Phases of Membrane Fusion
2007
Hepatitis C Virus Glycoprotein E2 Contains a Membrane-proximal Heptad Repeat Sequence That Is Essential for E1E2 Glycoprotein Heterodimerization and Viral Entry
2004
Delivery of a foreign epitope by sharing amino acid residues with the carrier matrix
2009
Determinants of CD81 dimerization and interaction with hepatitis C virus glycoprotein E2
2005
High incidence of hepatitis C virus reinfection in a cohort of injecting drug users
2008
Mutagenesis of a conserved fusion peptide-like motif and membrane-proximal heptad-repeat region of hepatitis C virus glycoprotein E1
2007
Hepatitis C Virus Nonstructural Protein 5B Is Involved in Virus Morphogenesis
2012
An Optimized Hepatitis C Virus E2 Glycoprotein Core Adopts a Functional Homodimer That Efficiently Blocks Virus Entry
2016
Induction of neutralizing antibody responses to hepatitis C virus with synthetic peptide constructs incorporating both antibody and T‐helper epitopes
2007
Monoclonal Antibodies Directed toward the Hepatitis C Virus Glycoprotein E2 Detect Antigenic Differences Modulated by the N-Terminal Hypervariable Region 1 (HVR1), HVR2, and Intergenotypic Variable Region
2015
Expression and Characterization of a Minimal Hepatitis C Virus Glycoprotein E2 Core Domain That Retains CD81 Binding
2007
Distinct roles in folding, CD81 receptor binding and viral entry for conserved histidine residues of hepatitis C virus glycoprotein E1 and E2
2012
In silico directed mutagenesis identifies the CD 81/claudin‐1 hepatitis C virus receptor interface
2012
A Conserved Gly436-Trp-Leu-Ala-Gly-Leu-Phe-Tyr Motif in Hepatitis C Virus Glycoprotein E2 Is a Determinant of CD81 Binding and Viral Entry
2006
Immunizations with Chimeric Hepatitis B Virus-Like Particles to Induce Potential Anti-Hepatitis C Virus Neutralizing Antibodies
2007
Recent Advances in Our Understanding of Receptor Binding, Viral Fusion and Cell Entry of Hepatitis C Virus: New Targets for the Design of Antiviral Agents
2007
Identification of the Hepatitis C Virus E2 Glycoprotein Binding Site on the Large Extracellular Loop of CD81
2002
Role of Conserved Cysteine Residues in Hepatitis C Virus Glycoprotein E2 Folding and Function
2012
TCD8 response in diverse outcomes of recurrent exposure to hepatitis C virus
2009
Identification of a Residue in Hepatitis C Virus E2 Glycoprotein That Determines Scavenger Receptor BI and CD81 Receptor Dependency and Sensitivity to Neutralizing Antibodies
2008
Exploiting Information Inherent in Binding Sites of Virus-Specific Antibodies: Design of An HCV Vaccine Candidate Cross-Reactive with Multiple Genotypes
2006